ASAH1 and colorectal carcinoma: Analyses of the neoantigen landscape showed that neoantigens from tandem duplications from acid ceramidase (ASAH1) were predicted in 25% of the PDOs (Table S2), suggesting that this public neoantigen can be used for developing therapeutic vaccination using off-the-shelf vaccine for this CRC cohort.